Provided is a Cannabis plant exhibiting altered tetrahydrocannabinolic acid (THCA) and/or cannabidiolic acid (CBDA) content. The plant includes a modified genomic locus involved in tetrahydrocannabinolic acid synthase (THCAS) and/or cannabidiolic acid synthase (CBDAS) gene expression, the genomic locus includes at least one targeted nucleotide modification within a regulatory region modulating the expression of at least one allele of the THCAS and/or CBDAS genes. Further provided are methods for producing the aforementioned Cannabis plant.

Provided herein are cannabinoid-ratio defined formulations suitable for use as an active pharmaceutical ingredient. Also provided are methods of making the cannabinoid-ratio defined formulations; pharmaceutical compositions comprising the cannabinoid-ratio defined formulations, and methods of using the pharmaceutical compositions for the treatment of Parkinsonian movement disorders, including Parkinson’s disease, parkinsonism, and dopamine-related Parkinson’s disease symptoms.

Provided herein are cannabinoid-ratio defined formulations suitable for use as an active pharmaceutical ingredient. Also provided are methods of making the cannabinoid-ratio defined formulations; pharmaceutical compositions comprising the cannabinoid-ratio defined formulations, and methods of using the pharmaceutical compositions for the treatment of Parkinsonian movement disorders, including Parkinson’s disease, parkinsonism, and dopamine-related Parkinson’s disease symptoms.

A composition for treating COVID-19 and/or acute respiratory failure (ARF) and/or acute respiratory distress syndrome (ARDS) (optionally caused in a subject afflicted with COVID-19) in a subject in need thereof is provided, along with a method of treating. The method includes administering to the subject a therapeutically effective amount of a composition or combination including a tetrahydrocannabinol (THC), derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof and a fluvoxamine, derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof.

The current invention relates to compositions and methods for treating head lice using compounds extracted from Cannabis sativa. The method can include a formulation including a compound extracted from cannabis and coconut oil.

The present invention is directed to a pharmaceutical composition, including a method of using same, such as for treating or attenuating a mood disorder in a subject having a high inflammatory state. The pharmaceutical composition and the method of the invention, in some embodiments thereof, comprise suppressing or inhibiting microglia for treating a mood disorder.

An oral soluble film contains at least one active agent. Alternatively, a multi-layered film includes a plurality of layers, at least one at least one of the plurality of layers being an oral soluble film layer containing at least one active agent. The oral soluble film may be made, e.g., by a method comprising providing a well of a predetermined size; depositing a film forming composition in the well; metering a predetermined amount of an active agent composition in the well separately from the film forming composition, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming a single layer in the well; and drying the single layer in the well to form the oral soluble film containing the at least one active agent. In some embodiments, a film made by deposit includes at least one non-cannabinoid bioactive agent and at least one cannabinoid.

The present invention is in the field of antioxidants and relates to cosmetic or pharmaceutical, preferably dermatological, compositions or homecare product comprising or consisting of a synergistic combination of a specific antioxidant and an effective amount of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or homecare product, in particular for scavenging reactive oxygen species (ROS), for inhibition matrix metalloproteinases expression and/or for inhibiting interleukin 8 (IL-8) secretion. Additionally, the present invention relates to the use of 1,2-heptanediol and/or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols for enhancing the antioxidative effect of an antioxidant in a cosmetic or pharmaceutical, preferably dermatological, composition or homecare product, and/or for enhancing the antioxidative effect of a cosmetic or pharmaceutical, preferably dermatological, composition upon application.

Pharmaceutical formulations and treatments are provided that make combined use of selected antibiotic cannabinoids with silver-containing medicaments. Therapeutically effective regimens are provided that facilitate positive drug-drug interactions between the cannabinoid and the silver-containing medicament in a subject.

Provided herein are methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, for example, in the treatment of a mental health disorder or chronic inflammatory disease.

##STR00001##